Trial Profile
Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs EA 230 (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacodynamics
- 28 Mar 2019 Results published in the British Journal of Clinical Pharmacology
- 22 Jun 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.